[1] |
DISTEFANO JK. NAFLD and NASH in postmenopausal women: Implications for diagnosis and treatment[J]. Endocrinology, 2020, 161( 10): bqaa134. DOI: 10.1210/endocr/bqaa134.
|
[2] |
BENCE KK, BIRNBAUM MJ. Metabolic drivers of non-alcoholic fatty liver disease[J]. Mol Metab, 2021, 50: 101143. DOI: 10.1016/j.molmet.2020.101143.
|
[3] |
KLAIR JS, YANG JD, ABDELMALEK MF, et al. A longer duration of estrogen deficiency increases fibrosis risk among postmenopausal women with nonalcoholic fatty liver disease[J]. Hepatology, 2016, 64( 1): 85- 91. DOI: 10.1002/hep.28514.
|
[4] |
Menopausal Group of Obstetrics and Gynecology Branch of Chinese Medical Association. The 2023 Chinese menopause symptom management and menopausal hormone therapy guidelines[J]. Chin J Obstet Gynecol, 2023, 58( 1): 4- 21. DOI: 10.3760/cma.j.cn112141-20221118-00706.
中华医学会妇产科学分会绝经学组. 中国绝经管理与绝经激素治疗指南2023版[J]. 中华妇产科杂志, 2023, 58( 1): 4- 21. DOI: 10.3760/cma.j.cn112141-20221118-00706.
|
[5] |
National Workshop on Fatty Liver and Alcoholic Liver Disease, Chinese Society of Hepatology, Chinese Medical Association; Fatty Liver Expert Committee, Chinese Medical Doctor Association. Guidelines of prevention and treatment for nonalcoholic fatty liver disease: A 2018 update[J]. J Clin Hepatol, 2018, 34( 5): 947- 957. DOI: 10.3969/j.issn.1001-5256.2018.05.007.
中华医学会肝病学分会脂肪肝和酒精性肝病学组, 中国医师协会脂肪性肝病专家委员会. 非酒精性脂肪性肝病防治指南(2018年更新版)[J]. 临床肝胆病杂志, 2018, 34( 5): 947- 957. DOI: 10.3969/j.issn.1001-5256.2018.05.007.
|
[6] |
Liver Disease Committee, Chinese Association of Integrative Medicine. Guidelines for the diagnosis and treatment of liver fibrosis in integrative medicine practice(2019)[J]. J Clin Hepatol, 2019, 35( 7): 1444- 1449. DOI: 10.3969/j.issn.1001-5256.2019.07.007.
中国中西医结合学会肝病专业委员会. 肝纤维化中西医结合诊疗指南(2019年版)[J]. 临床肝胆病杂志, 2019, 35( 7): 1444- 1449. DOI: 10.3969/j.issn.1001-5256.2019.07.007.
|
[7] |
EDDOWES PJ, SASSO M, ALLISON M, et al. Accuracy of FibroScan controlled attenuation parameter and liver stiffness measurement in assessing steatosis and fibrosis in patients with nonalcoholic fatty liver disease[J]. Gastroenterology, 2019, 156( 6): 1717- 1730. DOI: 10.1053/j.gastro.2019.01.042.
|
[8] |
YOUNOSSI ZM, KOENIG AB, WYMER M, et al. Global epidemiology of nonalcoholic fatty liver disease-Meta-analytic assessment of prevalence, incidence, and outcomes[J]. Hepatology, 2016, 64( 1): 73- 84. DOI: 10.1002/hep.28431.
|
[9] |
ROBEVA R, MLADENOVIĆ D, VESKOVIĆ M, et al. The interplay between metabolic dysregulations and non-alcoholic fatty liver disease in women after menopause[J]. Maturitas, 2021, 151: 22- 30. DOI: 10.1016/j.maturitas.2021.06.012.
|
[10] |
LOBO RA, GOMPEL A. Management of menopause: A view towards prevention[J]. Lancet Diabetes Endocrinol, 2022, 10( 6): 457- 470. DOI: 10.1016/S2213-8587(21)00269-2.
|
[11] |
GEORGIOPOULOS G, KONTOGIANNIS C, STAKOS D, et al. Abdominal fat tissue echogenicity: A marker of morbid obesity[J]. J Clin Endocrinol Metab, 2019, 104( 2): 301- 311. DOI: 10.1210/jc.2018-01301.
|
[12] |
JEONG HG, PARK H. Metabolic disorders in menopause[J]. Metabolites, 2022, 12( 10): 954. DOI: 10.3390/metabo12100954.
|
[13] |
WANG XY, WANG LH, DI JL, et al. Prevalence and risk factors for menopausal symptoms in middle-aged Chinese women: A community-based cross-sectional study[J]. Menopause, 2021, 28( 11): 1271- 1278. DOI: 10.1097/GME.0000000000001850.
|
[14] |
WU YJ, ZHANG WS, ZHU F, et al. Correlation between natural menopause age and postmenopausal metabolic syndrome[J]. Chin J Prev Med, 2023, 57( 3): 433- 437. DOI: 10.3760/cma.j.cn112150-20220601-00560.
吴永君, 张维森, 朱峰, 等. 自然绝经年龄与绝经后代谢综合征的相关性研究[J]. 中华预防医学杂志, 2023, 57( 3): 433- 437. DOI: 10.3760/cma.j.cn112150-20220601-00560.
|
[15] |
MENG X, LI SY, DUAN WH, et al. Secular trend of age at menarche in Chinese adolescents born from 1973 to 2004[J]. Pediatrics, 2017, 140( 2): e20170085. DOI: 10.1542/peds.2017-0085.
|
[16] |
WU ZY, XU YW, ZHANG LM. Correlation analysis of liver fibrosis with menopausal time and estrogen deficiency time in female patients with NAFLD[J]. Chin Hepatol, 2019, 24( 10): 1182- 1184. DOI: 10.14000/j.cnki.issn.1008-1704.2019.10.032.
吴宗妍, 徐优文, 张立梅. NAFLD女性患者肝纤维化与绝经时间和雌激素缺乏时间的相关性分析[J]. 肝脏, 2019, 24( 10): 1182- 1184. DOI: 10.14000/j.cnki.issn.1008-1704.2019.10.032.
|
[17] |
WEGERMANN K, GARRETT ME, ZHENG JY, et al. Sex and menopause modify the effect of single nucleotide polymorphism genotypes on fibrosis in NAFLD[J]. Hepatol Commun, 2021, 5( 4): 598- 607. DOI: 10.1002/hep4.1668.
|
[18] |
LEE YH, SON JY, KIM KS, et al. Estrogen deficiency potentiates thioacetamide-induced hepatic fibrosis in sprague-dawley rats[J]. Int J Mol Sci, 2019, 20( 15): 3709. DOI: 10.3390/ijms20153709.
|
[19] |
DOTLIC J, NICEVIC S, KURTAGIC I, et al. Hormonal therapy in menopausal transition: Implications for improvement of health-related quality of life[J]. Gynecol Endocrinol, 2020, 36( 4): 327- 332. DOI: 10.1080/09513590.2019.1676409.
|
[20] |
CAI XY, ZHANG ZJ. Pharmacological effects of phytoestrogens and research progress of related traditional Chinese medicine[J]. Res Pract Chin Med, 2020, 34( 2): 75- 78, 86. DOI: 10.13728/j.1673-6427.2020.02.015.
蔡心银, 张紫佳. 植物雌激素药理作用及相关中药的研究进展[J]. 现代中药研究与实践, 2020, 34( 2): 75- 78, 86. DOI: 10.13728/j.1673-6427.2020.02.015.
|